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Hereditary nonpolyposis colorectal cancer (HNPCC) describes the condition of a disparate group of families that
have in common a predisposition to colorectal cancer in the absence of a premalignant phenotype. The genetic
basis of this disease has been linked to mutations in genes associated with DNA mismatch repair. A large proportion
of families harbor changes in one of two genes, hMSH2 and hMLH1. Approximately 35% of families in which
the diagnosis is based on the Amsterdam criteria do not appear to harbor mutations in DNA-mismatch-repair
genes. In this report we present data from a large series of families with HNPCC and indicate that there are subtle
differences between families that harbor germline changes in hMSH2 and families that harbor hMLH1 mutations.
Furthermore, there are differences between the mutation-positive group (hMSH2 and hMLH1 combined) of families
and the mutation-negative group of families. The major findings identified in this study focus primarily on the
extracolonic disease profile observed between the mutation-positive families and the mutation-negative families.
Breast cancer was not significantly overrepresented in the hMSH2 mutation-positive group but was overrepresented
in the hMLH1mutation-positive group and in the mutation-negative group. Prostate cancer was not overrepresented
in the mutation-positive groups but was overrepresented in the mutation-negative group. In age at diagnosis of
colorectal cancer, there was no difference between the hMSH2 mutation–positive group and the hMLH1 muta-
tion–positive group, but there was a significant difference between these two groups and the mutation-negative
group.
Introduction
Hereditary nonpolyposis colorectal cancer (HNPCC
[MIM 120435 andMIM 120436]) is an autosomal dom-
inantly inherited disorder that is characterized primarily
by the development of early-onset colorectal cancer
(CRC) and that is also associated with the development
of a variety of epithelial tumors that include endometrial
cancer, stomach cancer, and ovarian cancer (Watson and
Lynch 1993). The genetic basis of HNPCC has been
linked to errors in DNA mismatch repair (Fishel et al.
1993; Leach et al. 1993; Bronner et al. 1994; Nicolaides
et al. 1994), which leaves a characteristic tumor signa-
Received September 26, 2000; accepted for publication November
1, 2000; electronically published December 7, 2000.
Address for correspondence and reprints: Dr. Rodney J. Scott, Hun-
ter Area Pathology Service, John Hunter Hospital, Lookout Road,
New Lambton, NSW 2305, Australia. E-mail: rscott@doh.health.nsw
.gov.au
 2001 by The American Society of Human Genetics. All rights reserved.
0002-9297/2001/6801-0011$02.00
ture, of DNA microsatellite instability, that can be used
as a surrogate marker for this syndrome (Ionov et al.
1993; Thibodeau et al. 1993). At least five genes have
been associated with DNA mismatch repair and
HNPCC; they are hMSH2, hMLH1, hMSH6, hPMS1,
and hPMS2 (for review, see Papadopoulos and Lind-
blom 1997). Together, hMSH2 and hMLH1 account for
50%–60% of all mutations in families in which diag-
nosis is based on the Amsterdam criteria—three relatives
with CRC, one of whom must be a first-degree relative
of the other two; CRC present in at least two genera-
tions; CRC diagnosed in one relative at age !50 years;
and familial adenomatous polyposis (FAP) not present.
Of families with HNPCC, 2%–20% of those which are
defined on the basis of the Bethesda criteria (excluding
the Amsterdam-criteria families) show association with
mutations in these two genes (Buerstedde et al. 1995;
Wijnen et al. 1998; Heinimann et al. 1999; Syngal et al.
1999). The contribution of hPMS1 (now considered to
be a pseudogene), hPMS2, and hMSH6 remains unde-
fined; however, on the basis of current evidence, hPMS2
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and hMSH6 appear to account for the condition in
∼5% of all families with HNPCC (Liu et al. 1996; Pel-
tomaki and Vasen 1997). The remaining 30%–40% of
Amsterdam-criteria families that do not evidently harbor
germline mutations in the genes described either contain
cryptic alterations within their coding regions, harbor
changes in promoter/enhancer regions, or have muta-
tions in other genes, which await identification (Papa-
dopoulos and Lindblom 1997).
The identification of families with HNPCC remains
problematic, despite knowledge about the genetic basis
of the disease. Several criteria have been proposed,
which are aimed at identification of families with a high
probability of harboring germline mutations in DNA-
mismatch-repair genes. To date, the accumulated evi-
dence indicates that by far the most accurate method
of family identification is use of the Amsterdam crite-
ria. Deviation from these criteria appears to result in a
poor mutation-detection rate, even when other tumors
that have been clearly defined within the spectrum of
HNPCC substitute for CRC (Wijnen et al. 1998; Hein-
imann et al. 1999).
Unlike FAP, in which genotype-phenotype correla-
tions have been described, no such obvious relation-
ship appears to be apparent in HNPCC. More-subtle
differences have been described, indicating that there
may be histological differences between hMSH2 mu-
tation–associated tumors and hMLH1 mutation–
associated tumors in HNPCC (Shashidharan et al.
1999)—and, indeed, that there may be clinical differ-
ences as well (Vasen and Wijnen 1999).
In this report we further characterize the relationship
between HNPCC and the likelihood of identification of
a germline mutation in either hMSH2 or hMLH1, and
we compare the features displayed in families that are
either mutation positive or mutation negative. Further-
more, a comparison between hMSH2 mutation–positive
families and hMLH1 mutation–positive families is made
that suggests that there may be some subtle differences
between these two HNPCC groups. Finally, in compar-
ing differences between the mutation-positive groups and
the mutation-negative group, we were able to establish
that, in disease phenotype, the mutation-negative group
resembles the hMLH1 mutation–positive group more
closely than it resembles the hMSH2 mutation–positive
group. This evidence suggests that proteins, which inter-
act with and affect hMLH1, could be good candidates
for genetic analysis.
Patients and Methods
Index patients from 95 families enrolled in this study
signed an informed-consent document (which, prior to
use, was assessed by the appropriate institutional re-
view body) authorizing genetic testing of genes associ-
ated with HNPCC. Cascade testing was performed on
family members after they too had given informed con-
sent for testing when a germline mutation had been iden-
tified in the family. Each pedigree was classified as either
Amsterdam-criteria positive or Bethesda-criteria posi-
tive. Genetic analysis was performed on a fresh blood
specimen from the youngest living affected proband in
each family. Disease verification in affected individuals
was based on either examination of pathology reports
or death certificates.
hMSH2 and hMLH1 Molecular Analysis
DNA was isolated from 20 ml of peripheral blood
lymphocytes, by the salting-out method first described
byMiller et al. (1988). All 35 exons constituting hMSH2
and hMLH1 were analyzed by denaturing gradient gel
electrophoresis, as described by Wijnen et al. (1995;
1996). In brief, each exon was amplified by PCR using
specific primers, which have incorporated into either one
of their 5′ ends a 40-bp GC clamp. The resulting PCR
product was applied to a denaturing gradient gel and
was subjected to electrophoresis for 15 h. Then the
gels were stained with ethidium bromide (1 mg/ml) and
were photographed on a UV-Trans-illuminator. All poly-
morphisms were subjected to DNA sequencing by a
semiautomated sequencing unit (PE Biosystems model
310), to determine the precise genetic change. Sequence
alterations were analyzed for the presence of pathogenic
mutations (nonsense, insertion, or deletion mutations).
Sequence changes with a frequency of 15% were con-
sidered to be normal variants and were described as
such. Polymorphisms that occurred at a frequency of
!5% were considered to represent changes that were
most likely to be associated with an increased predis-
position to develop early-onset HNPCC.
Statistical Analysis
Logistic regression with a correction for clusteringwas
used to determine whether there were differences be-
tween the groups (Royall 1986). This allows the detec-
tion of differences, with regard to the occurrence of can-
cer, between mutation groups. In addition to the indi-
vidual records on file, the records of each family’s dis-
ease-free individuals were included in the analysis, thus
reflecting the total number of individuals in each family.
A similar analysis was performed for each cancer type.
If there were no cases of a certain type of cancer, Fisher’s
exact test was performed to obtain some measure of the
degree of association. Data analyses were performed by
means of the STATA statistical package (version 6). The
typical STATA command for a logistic regression was
xi: logit ycrc i.mutation [fweightpn], cluster (id), where
ycrc is a binary variable indicating whether an individual
has had a history of the cancer type (in this case, CRC).
Table 1
Genetic Changes Identified in the hMLH1 and hMSH2 Genes
Gene and Family Exon/Intron Position(s) Mutation Type Nucleotide Change Consequence of Mutation Reference
hMLH1:
1 1 116 1-bp substitution GrA Splice site Farrington et al. (1998)
2 1 1 1-bp substitution ArG Loss of translation start site Wehner et al. (1997)
3 1 112 1-bp substitution ArG ArgrSer Present study
4 3 2, 1, 208, 209 4-bp deletion 4-bp deletion Loss of intron/exon junction Present study
5 4 350 1-bp substitution CrT ThrrMet Maliaka et al. (1996)
6 4 381 1-bp substitution GrA Loss of intron/exon junction Present study
7 7 554 1-bp substitution TrG ValrGly Kohonen-Corish et al. (1996)
8 8 673 1-bp deletion G deletion Frameshift/stop Present study
9 8 655 1-bp substitution ArG IlerVal (polymorphism) Hutter et al. (1998)
10 9 790 1-bp substitution ArG Splice site Liu et al. (1995)
11 12 1164 4-bp insertion Need info Stop codon Present study
12 13 13 1-bp substitution TrA Cryptic splice site Present study
13 13 1554 1-bp insertion T insertion Stop codon Present study
14 13 1535 1-bp substitution GrT Stop codon Present study
15 13 1460 4-bp deletion TGAT deletion Stop codon Present study
16 16 1731 1-bp substitution GrA Splice site Present study
17 16 1852 2-bp substitution AArGC AlarLys Present study
18 17 1959 1-bp substitution GrT Splice site Present study
19 17 1989 1-bp substitution GrA Stop Present study
20 17 1975 2-bp deletion GA deletion Stop codon Present study
21 19 2253 1-bp substitution ArG LysrArg Present study
22 19 2147 1-bp substitution GrA ValrMet Wehner et al. (1997)
hMSH2:
23 6 1009 1-bp substitution CrT Stop codon Present study
24 6 965 1-bp substitution GrA GlyrAsp Maliaka et al. (1996)
25 6 984 1-bp substitution CrT AlarAla (polymorphism)
26 8 1381 Inversion and substitution Complexa Nonsense segment Present study
27 9 1408 1-bp deletion G deletion Stop codon Present study
28 9 1510 1-bp substitution GrC Splice site change Present study
29 10 12 from exon 10 1-bp substitution ArG Cryptic splice site Present study
30 11 1669 1-bp substitution TrC LeurLeu (polymorphism) Wijnen et al. (1995)
31 12 1968 1-bp substitution GrC Stop codon Kohonen-Corish et al. (1996)
32 13 2157 1-bp substitution ArG GlnrGln (polymorphism)
33 13 2051 66-bp duplication Complexb Reiteration Present study
34 15 2502 7-bp deletion Loss of TAATTTC Stop codon Present study
a See figure 1a.
b See figure 1b.
Scott et al.: Mutation Status and Disease in HNPCC 121
Figure 1 Complex DNA sequence changes identified in hMSH2
Table 2
Mutation Status of Bethesda- and Amsterdam-Criteria Families
CRITERION
NO. OF FAMILIES
PROPORTION OF
FAMILIES THAT
ARE POSITIVE
Mutation
Negative
Mutation
Positive
hMSH2 hMLH1
Bethesda 50 6 6 19.4%
Amsterdam 13 9 11 60.6%
Overall 63 15 17 33.7%
All other statistical analysis was performed by means of
Student’s t-test.
Results
Mutation-Positive Families
Of the 95 families, 12 harbored a genetic change in
the hMSH2 gene, 22 harbored a change in the hMLH1
gene, and 61 were found not to harbor any change in
either gene. The precise genetic changes identified in the
hMLH1 gene and the hMSH2 gene are shown in table
1. No particular types of genetic change were overre-
presented in our mutation/polymorphism data set. The
ratio of observed hMSH2 genetic changes to hMLH1
genetic changes was almost 1:2. A spectrum of changes
was identified in the hMLH1 gene; these included four
nonsense mutations and three substitutions that resulted
in stop codons, seven splice-site changes that resulted in
exon skipping, six missense mutations, one loss of an
ATG start site, and one 2-bp substitution that led to an
AlarLys change. Similar changes were identified in the
hMSH2 gene, which included five nonsense mutations
and one substitution, all of which resulted in stop co-
dons, one missense mutation; three 1-bp substitutions
that did not result in any amino acid change; and two
complex mutations. The two complex changes identified
in hMSH2 were (a) an inversion of bases 1338–1361,
substituting for bases 1311–1334 inclusive in exon 8,
and (b) a large duplication of 66 bp in exon 13, at
position 2048, both of which are predicted to result in
a segment of nonfunctional peptide within the hMSH2
protein. The sequence of these two changes is shown in
figure 1. In neither family were there any special features
that could be related to the uniqueness of either
mutation.
The polymorphisms identified in this study were
checked against The International Collaborative Group
on Hereditary NonPolyposis Colorectal Cancer muta-
tion database, to determine whether they could be as-
signed causative status. Of the seven missense changes
in hMLH1 (see table 1), four had been identified in pre-
vious reports, with three having been reported as being
causative (Kohonen-Corish et al. 1996; Maliaka et al.
1996; Wehner et al. 1997) and one having been reported
as being polymorphic (Hutter et al. 1998). The three
remaining changes in hMLH1 are of unknown status.
In a previous report (Maliaka et al. 1996), three of the
missense mutations identified in hMSH2 (table 1) had
been shown to be polymorphisms of no apparent con-
sequence, and one had been described as pathogenic.
Since tumor tissue was not available from all patients
harboring missense mutations, microsatellite-instability
analysis for assignment of causation could not be per-
formed. Nevertheless, none of the new missense muta-
tions were detected in 50 control subjects, indicating that
these changes may be associated with a change of protein
function.
One family was identified as having Muir-Torre syn-
drome, since (a) one of its members presented with a
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Table 3
Relative Percentage of Tumor Types in the Study Population
CANCER TYPE
NO. (PERCENTAGE) IN STUDY POPULATION
Total
Mutation
Negative
Mutation Positive
hMSH2 hMLH1
CRC 316 (9.86) 213 (9.80) 73 (8.92) 66 (12.15)
Endometrial/ovarian 50 (1.37) 36 (1.65) 7 (.79) 7 (1.29)
Stomach 41 (1.12) 26 (1.1) 9 (1.02) 6 (1.19)
Brain/CNS tumors 14 (.38) 11 (.5) 3 (.34) …
Breast 55 (1.5) 44 (2.02) 2 (.22) 9 (1.66)
Renal/renal-tract 18 (.50) 9 (.410 7 (.8) 2 (.37)
Lymphoproliferativea 18 (.50) 13 (.60) 2 (.23) 3 (.55)
Prostate 11 (.30) 10 (.46) 1 (.11) …
a Includes all lymphoproliferative cancers exceptHodgkin leukemia.
Table 4
SIRs of Cancers Identified in All Families, as a Function of Mutational Status
CANCER TYPE
MUTATION-POSITIVE PATIENTS
ALL PATIENTS hMSH2 hMLH1
MUTATION-NEGATIVE
PATIENTS
No. SIR (95% CI) No. SIR (95% CI) No. SIR (95% CI) No. SIR (95% CI)
CRC 361 159.54 (139.2–182.9) 73 134.24 (99.1–181.8) 66 196.76 (143.0–270.7) 213 158.61 (132.8–189.4)
Endometrial/ovarian 50 53.35 (37.0–77.0) 7 31.08 (11.7–82.9) 7 50.39 (18.9–134.3) 36 64.72 (42.0–99.7)
Stomach 41 102.2 (68.2–153.28) 9 93.35 (39.3–221.6) 6 100.89 (35.0–290.8) 26 109.20 (65.7–181.6)
Brain/CNS tumors 14 56.02 (28.0–112.0) 3 49.95 (11.2–223.2) … … 11 74.16 (33.9–162.0)
Breast 55 13.38 (9.4–19.0) 2 2.02 (.3–12.7)a 9 14.77 (6.2–35.0) 44 18.03 (12.2–26.7)
Renal/renal-tract 18 42.17 (22.9–77.7) 7 68.24 (25.7–181.8) 2 31.6 (5.1–197.6) 9 35.53 (15.0–84.3)
Lymphoproliferativeb 18 13.93 (7.6–25.7) 2 6.44 (1.0–40.3) 3 15.66 (3.5–290.1) 13 16.95 (8.3–34.8)
Prostate 11 2.69 (1.2–5.8) 1 1.02 (.1–13.6)a … … 10 4.12 (1.8–9.4)
a Not significantly different from the expected value.
b Includes all lymphoproliferative cancers except Hodgkin leukemia.
sebaceous adenoma and (b) there was a strong family
history of CRC, which fulfilled the Amsterdam criteria.
The proband harbored a silent polymorphism in exon
11 of hMSH2 but did not appear to harbor any other
change in either hMSH2 or hMLH1.
When mutation status based on the Amsterdam cri-
teria was compared with that based on the Bethesda
criteria, differences between the two groups were ob-
served. As expected, 60% of Amsterdam-criteria families
were mutation positive, compared with 20% of Be-
thesda-criteria families (see table 2). There appeared to
be no relationship, between the sites of mutations, that
could be used to establish a genotype-phenotype cor-
relation, for either hMLH1 or hMSH2. Within each of
the two groups, a comparison between the age at onset
of CRC, the spectrum of extracolonic disease, and how
this related to the mutation-negative group was made.
Cancer Occurrence
The overall percentage of tumors observed—in the
total population, in the mutation-negative group, and
in the hMSH2 mutation–positive and hMLH1 muta-
tion–positive groups—is shown in table 3. In the total
population, the most frequently observed tumor was
CRC, followed by breast cancer, endometrial cancer, and
stomach cancer. Other cancers common toHNPCCwere
also overrepresented. The relative standardized inci-
dence rates (SIRs), including 95% confidence intervals
(95% CIs), for all cancers identified in each group are
shown in table 4. When the study population was sub-
divided into hMSH2 mutation–positive, hMLH1 mu-
tation–positive, and mutation-negative groups, similar-
ities and differences between the three groups could be
identified.
CRC
Of the 95 families, 32 fulfilled the Amsterdam crite-
ria and 63 fulfilled the Bethesda criteria. The clinical
features of each of the probands are shown in table 5.
The age at diagnosis of CRC in the three groups of
patients is shown in figure 2 (mutations of uncertain
significance were not included). The age distributions of
the hMSH2 mutation–positive group and the hMLH1
mutation–positive group were essentially identical, but
there was an ∼5-year shift in the distribution seen in the
mutation-negative group. The average age (SD) at di-
agnosis in hMSH2 mutation-positive families was 45.77
(24.35) years, and that in hMLH1 mutation-positive
families was 47.16 (18.65) years. There was no sta-
tistical difference between the two groups ( )Pp .747
when we adjusted for familial clustering. The average
age at diagnosis in the mutation-negative group was
52.68 (17.65) years, which was significantly different
from that in the hMSH2 mutation-positive group but
was not statistically different from that in the hMLH1
mutation-positive group ( and .135, respec-Pp .031
tively). Compared with the median age of diagnosis of
CRC (peak incidence being diagnosed during the 7th
and 8th decades of life), all three groups had an age at
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Table 5
Clinical Features of Probands Selected for Mutation Analysis
Proband
Age at
Diagnosis
(years) Tumor Type
Family
History
of Cancer? a
Amsterdam
Criteria
Positive?
1 27 CRC Yes Yes
2 48 CRC Yes No
3 65 CRC Yes No
4 46 CRC No No
5 45 CRC Yes Yes
6 55 Stomach Yes Yes
7 47 CRC Yes No
8 52 CRC Yes Yes
9 39 CRC Yes No
10 51 CRC Yes No
11 59 CRC Yes No
12 37 CRC Yes Yes
13 31 CRC No No
14 46 CRC Yes No
15 55 CRC Yes No
16 36 CRC Yes Yes
17 52 CRC Yes No
18 41 CRC Yes Yes
19 48 CRC Yes No
20 26 CRC Yes No
21 25 CRC Yes No
22 64 CRC Yes Yes
23 58 Adenomas Yes No
24 32 CRC Yes Yes
25 47 CRC Yes Yes
26 17 CRC Yes No
27 40 Stomach Yes No
28 44 CRC Yes No
29 41 CRC Yes No
30 46 CRC Yes No
31 19 Adenomas Yes Yes
32 52 CRC Yes No
33 43 CRC Yes No
34 37 Endometrial cancer Yes Yes
35 66 CRC Yes No
36 38 CRC Yes Yes
37 48 CRC Yes Yes
38 47 Endometrial cancer Yes Yes
39 35 Adenomas Yes No
40 66 CRC Yes No
41 74 CRC Yes No
42 49 CRC Yes Yes
43 31 CRC Yes No
44 44 CRC Yes Yes
45 27 CRC Yes No
46 51 CRC Yes No
47 58 CRC Yes Yes
48 56 CRC Yes No
49 28 CRC Yes Yes
50 45 CRC No No
51 31 CRC Yes No
52 25 CRC Yes Yes
53 53 CRC Yes No
54 69 CRC Yes No
55 62 CRC Yes Yes
56 45 CRCb Yes Yes
57 50 CRC Yes Yes
(continued)
Proband
Age at
Diagnosis
(years) Tumor Type
Family
History
of Cancer? a
Amsterdam
Criteria
Positive?
58 24 CRC Yes Yes
59 48 CRC Yes Yes
60 35 CRC Yes No
61 54 CRC Yes No
62 43 CRC Yes No
63 57 Adenomas Yes No
64 41 CRC Yes Yes
65 56 CRC Yes Yes
66 62 CRC Yes No
67 68 Adenomas Yes No
68 32 CRC Yes No
69 55 CRC Yes Yes
70 55 Stomach Yes Yes
71 29 Stomach Yes No
72 40 Endometrial cancer Yes Yes
73 45 Adenomas Yes No
74 45 CRC Yes Yes
75 57 Adenomas Yes No
76 13 CRC Yes No
77 54 Adenomas Yes No
78 40 CRC Yes No
79 33 CRC Yes No
80 36 CRC Yes No
81 61 CRC Yes No
82 65 Adenomas Yes No
83 38 CRC No No
84 32 CRC Yes No
85 30 CRC Yes No
86 52 CRC Yes No
87 63 CRC Yes No
88 44 CRC Yes No
89 54 CRC Yes No
90 78 Ovarian cancer Yes No
91 51 CRC Yes No
92 51 CRC Yes Yes
93 44 Stomach Yes No
94 50 CRC Yes No
95 30 CRC Yes No
a All patients without a family history had multiple primary colon
cancers; for these individuals, the age at diagnosis is that when CRC
was first diagnosed.
b Muir-Torre syndrome.
onset that was significantly younger than would have
been expected (Cancer in New South Wales: Incidence
and Mortality 1997 database). When the hMLH1 mu-
tation–positive group was compared with the hMSH2
mutation–positive group, there was a trend toward a
lower rate of CRC in the latter group, although this
trend was not statistically significant ( ).Pp .087
Extracolonic Cancers
The relative frequency of other malignancies associ-
ated with HNPCC is shown in figure 3. The frequen-
cies of the following cancer types were found not to
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Figure 2 Age at diagnosis in 292 patients with familial colorectal
carcinoma, according to mutation status. One to six affectedmutation-
positive family members were included in this analysis, and only
hMSH2 and hMLH1 causative mutations were included.
Figure 3 Relative percentage of malignancies within the three
groups of families with HNPCC. The tumor spectrum was determined
on the basis of 559 patients with cancer, all of whomwere from families
with a clustering of CRC.
differ between the hMSH2mutation–positive group, the
hMLH1 mutation–positive group, and mutation-nega-
tive group: lymphoproliferative disease, renal/renal-
tract cancers, endometrial/ovarian cancers, and stomach
cancer. All these malignancies were overrepresented in
all three groups, compared with the expected frequency
in the general population (see table 4). Differences in
SIR trends were apparent between the groups. Endo-
metrial cancer incidence was significantly increased,
compared with that in the general population, as were
stomach cancer, CNS tumors (in the mutation-nega-
tive group and the hMSH2 mutation–positive group
only), renal/renal-tract cancer, and lymphoproliferative
disease. Breast cancer was not overrepresented in the
hMSH2 mutation–positive group, but it was overrepre-
sented in both the hMLH1 mutation–positive group and
the mutation-negative group, which was a highly sig-
nificant difference. The SIR of breast cancer in the mu-
tation-negative group was similar to that observed in the
hMLH1mutation–positive group. Differences in the SIR
of prostate cancer were observed between the mutation-
negative group and the hMSH2mutation–positive group
(no cases were observed in the hMLH1 mutation–
positive group). This difference was significant, as de-
termined by Fisher’s exact test ( ), which indi-Pp .038
cated that there was a relatively high number of prostate
cancer patients in the mutation-negative group, com-
pared with both mutation-positive groups.
The age at diagnosis of breast cancer in the study
population does appear to be younger than expected.
The average age at diagnosis of breast cancer diagnosis
was 54.27 years in the overall population in this study;
in the mutation-negative group, it was 55.55 years; in
the hMLH1 mutation–positive group, 51.33 years; and
in the hMSH2 mutation–positive group, 54 years. This
age is ∼6 years younger than the average age, 60 years,
in New South Wales (Cancer in New South Wales: In-
cidence and Mortality 1997 database). Furthermore, we
determined that this malignancy was significantly more
likely to be present in the mutation-negative group and
in the hMLH1 mutation–positive group than in the
hMSH2 mutation–positive group ( ). Also,Pp .006
breast cancer was more likely to be identified in the
hMLH1 mutation–positive group than in the hMSH2
mutation–positive group ( ).Pp .024
When the occurrence of the cancer types was com-
pared overall, some similarities between the groups
could be identified, as shown in table 4. The spectrum
and frequency of malignancies in the hMLH1 muta-
tion–positive group more closely matched those in the
mutation-negative group than did those in the hMSH2
mutation–positive group. Interestingly, in the hMSH2
mutation–positive group the incidence of kidney and re-
nal-tract cancers was greater than that in either the
hMLH1 mutation–positive group or the mutation-neg-
ative group; however, this difference did not reach
significance.
Discussion
The identification of germline mutations in families with
HNPCC remains difficult, despite the fact that there have
been improvements in the technology of mutation de-
tection. In this report we have analyzed a large group
of patients (and their families, when available) for mu-
tations in the DNA-mismatch-repair genes hMLH1 and
hMSH2. Selection of families on the basis of the Am-
sterdam citeria remains the best method in which the
probability of mutation detection remains high, at
∼60%. When the criteria are extended to include a num-
ber of other facets, which are included among the Be-
thesda criteria, the mutation-detection rate falls to
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∼34%. Given that there have been several reports (Wi-
jnen et al. 1998; Heinimann et al. 1999) indicating that
relaxation of the Amsterdam criteria results in a poor
rate of identification of mutations, many groups are ad-
hering to the Amsterdam criteria when they select fam-
ilies for genetic-testing purposes. However, since ourmu-
tation-detection rate identified mutations in patients
who fulfilled the Bethesda criteria but not the Amster-
dam criteria, we would advocate that this group of pa-
tients should be screened for DNA-mismatch-repair–
gene alterations. Of particular note, two separate caus-
ative mutations were identified in two Bethesda-criteria
patients who presented with multiple colonic primaries
over a period of many years and who did not have a
family history of disease. There remain, however, in both
categories, a substantial proportion of families that have
an autosomal dominant disease pattern, which is best
accounted for by a single, highly penetrant disease allele.
Studies using denaturing gradient gel electrophoresis to
detect mutations in various genes suggest detection rates
of 90%–95% (Wahlberg et al. 1999). Therefore, we do
not believe that, in the identification of genetic change
within coding regions of the genes under investigation,
methodologies used in the present study are so deficient
that many changes in hMSH2 or hMLH1 have been
missed. Nevertheless, some changes will not be detect-
able when the strategy is employed; these are likely to
be changes in promoter or enhancer regions, cryptic
changes within noncoding sequences, and large deletions
encompassing either whole exons or the entire gene.
Two mutations in hMSH2 were of special interest:
(1) the 24-bp inversion and substitution, at positions
1311–1334 inclusive in exon 8, and (2) the 66-bp du-
plication at positions 2048–2114 in exon 13. Neither
of these mutations led to any unique phenotype—and,
presumably, neither results in altered hMSH2 function.
The best explanation for both of these mutations is a
recombination event that resulted in the inadvertent du-
plication of sequence. There was no apparent disease
phenotype that could be readily identified with any
particular mutation in this study, confirming the notion
that a breakdown in DNA mismatch repair is not as-
sociated with overt differences in disease phenotype.
Disease-spectrum differences associated with hMSH2 or
hMLH1 were, however, identified on examination of
the types of tumors present in families that harbored
either a hMLH1 mutation, a hMSH2 mutation, or no
mutation.
On average, the age at diagnosis of CRC in the mu-
tation-negative group was 5 years older than that in
the mutation-positive group, but the difference was sig-
nificant only in the hMSH2 mutation–positive group.
In the hMLH1 mutation–positive group, there was an
apparent trend toward ages at diagnosis that were
younger than those in the mutation-negative group, but
the difference did not reach statistical significance. In-
terestingly, in terms of the age at disease penetrance,
there was no difference between the hMSH2 muta-
tion–positive group and the hMLH1 mutation–positive
group, which indirectly supports the concept that
DNA mismatch repair is a caretaker function and not
a gatekeeper function (Kinzler and Vogelstein 1997).
This does not mean, however, that differences do not
exist between the two groups. The protein MSH2 has
been shown to be important in the recognition of DNA
mispairs and is an energy-driven process, whereas
MLH1 binds to MSH2:DNA complexes and helps to
orchestrate endonuclease activity (Fishel 1998). In ad-
dition, hMLH1 appears to be involved in meiotic re-
combination, giving it a multifunctional role (Anderson
et al. 1999). Given these subtle differences between the
two proteins, we studied the disease profiles of the
hMSH2 mutation–positive group and the hMLH1 mu-
tation–positive group. There was a tendency for the
frequency of CRC in the hMLH1 mutation–positive
group to be greater than that in the hMSH2 muta-
tion–positive group, with the relative percentages being
12.15 and 8.92, respectively. This suggests that, with
regard to CRC risk, there may be some differences be-
tween the two groups. A possible explanation for this
difference is the greater potential for allelic silencing in
hMLH1, by hypermethylation of the wild-type allele
(Cunningham et al. 1998). Nevertheless, except for
breast cancer and prostate cancer, the rates of other
cancers were similar in both groups, suggesting the pos-
sibility of colon-specific differences in disease expres-
sion. The frequency of breast cancer in the hMSH2mu-
tation–positive group was significantly less than that
observed in either the hMLH1mutation–positive group
or the mutation-negative group, suggesting a real dif-
ference between the three groups. There are conflict-
ing reports as to whether breast cancer risk is increased
in HNPCC (Itoh et al. 1990; Nelson et al. 1993;Watson
and Lynch 1993; Risinger et al. 1996). Breast cancer
incidence overall in our study population was overre-
presented within both the hMLH1 mutation–positive
group and the mutation-negative group but was not
overerepresented in the hMSH2 mutation–positive
group. Why breast cancer should be underrepresented
in the hMSH2 mutation–positive group is not known,
but it may be associated with the proposed roles of
hMLH1 and hMSH2 in the BRCA1-associated genome
surveillance complex supercomplex involved in the rec-
ognition and repair of aberrant DNA structures (Wang
et al. 2000). The finding that breast cancer does not
appear to be associated with hMSH2 mutations may
explain some of the discrepancies that have been re-
ported in the literature, with respect to breast cancer
risk in HNPCC.
As expected, the incidence of prostate cancer was not
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overrepresented in the mutation-positive groups consid-
ered together. Interestingly, a feature of the mutation-
negative group did appear to be the increased incidence
of prostate cancer, and this may therefore be a feature
of the families with HNPCC that are mutation negative.
Finally, the overall spectrum of disease within the
mutation-negative group more closely resembled that
observed in the hMLH1 mutation–positive group than
it resembled that in the hMSH2 mutation–positive
group. This, coupled with the similar ages at diagnosis
of CRC, suggests either that there are more-subtle
changes occurring in the hMLH1 gene that are not being
identified by mutation analysis or that other proteins
may interact with hMLH1, such that their disruption
results in a disease spectrum similar to that observed in
hMSH2 mutation–positive families.
In conclusion, use of the Bethesda criteria for the
selection of families for gene analysis results in a reduced
probability of mutation detection. Nevertheless, fami-
lies or patients that can be identified on the basis of
these criteria should be offered genetic testing for genes
associated with HNPCC, since this will result in an in-
creased rate of identification of gene-mutation carriers.
To improve the probability of mutation detection if the
Bethesda criteria are adopted, we would suggest that
mutation analysis be performed in conjunction with
DNA microsatellite testing and, possibly, immunohis-
tochemical staining for DNA-mismatch-repair pro-
teins. Subdivision of the mutation-positive and muta-
tion-negative groups makes it possible to tease out
subtle differences between the various populations, such
as similar ages at onset of disease in the mutation-neg-
ative and hMLH1 mutation–positive groups and dis-
ease-spectrum differences within eachmutation-positive
group. Better knowledge of the disease spectrum asso-
ciated with mutation status will aid in the management
of these families. Better classification of the mutation-
negative group will aid in identification of additional
genes associated with this disorder.
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